Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
复制标题
DOI：
10.3390/curroncol28050352
复制
发表时间：
2021-10-14
期刊：
影响因子：
--
通讯作者：
Seno H
中科院分区：
文献类型：
--
作者：
Eso Y;Takeda H;Taura K;Takai A;Takahashi K;Seno H
背景：抗程序性死亡配体 1 单克隆抗体 atezolizumab 加抗血管内皮生长因子药物贝伐单抗 (Atezo/Bev) 的联合治疗于 2020 年被批准作为不可切除的肝细胞癌 (HCC) 的一线治疗。 Atezo/Bev 疗法的耐受性相对较好；然而，尚未报道可以预测其反应的因素。因此，我们的目的是研究治疗前的中性粒细胞与淋巴细胞比率 (NLR) 是否可以预测接受 Atezo/Bev 治疗的 HCC 患者的治疗反应。方法：我们分析了 40 名在我们医院接受 Atezo/Bev 治疗的 HCC 患者的病程，并试图通过比较那些达到疾病控制的患者与那些未达到疾病控制的患者来确定可以预测缓解的治疗前因素。结果：疾病控制的患者治疗前NLR值显着低于疾病进展患者（2.47 vs. 4.48，p = 0.013）。使用受试者工作特征曲线分析确定的预测缓解的最佳 NLR 截止值 (3.21)，NLR ≤ 3.21 的患者比 NLR > 3.21 的患者具有显着更好的无进展生存期 (p < 0.0001)，尽管两组之间的肝功能或肿瘤相关背景因素没有显着差异。结论：治疗前 NLR 值可能是 Atezo/Bev 治疗 HCC 反应的有用预测因子。
Background: Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved in 2020 as a first-line treatment for unresectable hepatocellular carcinoma (HCC). Atezo/Bev therapy is relatively well tolerated; however, factors that can predict its response have not yet been reported. Thus, we aimed to investigate whether the pretreatment neutrophil-to-lymphocyte ratio (NLR) could predict the therapeutic response in patients with HCC treated with Atezo/Bev therapy. Methods: We analyzed the course of 40 patients with HCC who received Atezo/Bev therapy at our hospital and attempted to identify pretreatment factors that could predict response by comparing those who achieved disease control with those who did not. Results: The pretreatment NLR value in patients who achieved disease control was significantly lower than that in patients with disease progression (2.47 vs. 4.48, p = 0.013). Using the optimal NLR cut-off value for predicting response (3.21) determined by receiver operating characteristic curve analysis, patients with NLR ≤ 3.21 had significantly better progression-free survival than those with NLR > 3.21 (p < 0.0001), although there were no significant differences in liver function or tumor-related background factors between the two groups. Conclusions: The pretreatment NLR value may be a useful predictor of response to Atezo/Bev therapy for HCC.
登录
查看更多内容
影响因子：
10.9
作者：
Capone M;Giannarelli D;Mallardo D;Madonna G;Festino L;Grimaldi AM;Vanella V;Simeone E;Paone M;Palmieri G;Cavalcanti E;Caracò C;Ascierto PA
通讯作者：
Ascierto PA
影响因子：
158.5
作者：
Finn, Richard S.;Qin, Shukui;Cheng, Ann-Lii
通讯作者：
Cheng, Ann-Lii
影响因子：
5.3
作者：
Bagley, Stephen J.;Kothari, Shawn;Langer, Corey J.
通讯作者：
Langer, Corey J.
影响因子：
2.6
作者：
Gomez, D.;Farid, S.;Prasad, K. R.
通讯作者：
Prasad, K. R.
DOI：
10.1002/cnr2.1464
发表时间：
2022-03
期刊：
Cancer reports (Hoboken, N.J.)
影响因子：
--
作者：
Hiraoka A;Kumada T;Tada T;Hirooka M;Kariyama K;Tani J;Atsukawa M;Takaguchi K;Itobayashi E;Fukunishi S;Tsuji K;Ishikawa T;Tajiri K;Ochi H;Yasuda S;Toyoda H;Ogawa C;Nishimura T;Hatanaka T;Ohama H;Nouso K;Morishita A;Tsutsui A;Nagano T;Itokawa N;Okubo T;Arai T;Imai M;Koizumi Y;Nakamura S;Joko K;Iijima H;Hiasa Y;Kudo M;Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan)
通讯作者：
Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan)